Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 22 August 2022, 09:47 HKT/SGT
Share:
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes

HONG KONG, Aug 22, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has been selected as a constituent stock of eight index series including Hang Seng Composite Index ("HSCI"), Hang Seng Stock Connect Hong Kong Index ("HSHKI"), Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, Hang Seng Healthcare Index and Hang Seng Small Cap (Investable) Index by Hang Seng Indexes Company Limited, with effect from 5 September 2022.

HSCI offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks, and assists international and local investors in formulating investment strategies. Inclusion into the HSCI will allow the Company's stock to be eligible for trading on the Hong Kong Stock Connect, a channel for stock trading between investors in Hong Kong and those in mainland China. HSHKI serves as a benchmark to reflect the overall performance of the securities listed in Hong Kong that are eligible for trading via the southbound trading link of Stock Connect. It covers equities eligible for trading via such scheme, with additional liquidity screening to make the covered equities a more investable reference set for mainland China investors.

The selection of the Company as a constituent stock of the above-mentioned index series of Hang Seng Indexes Company Limited is expected to be conducive in introducing more diversified investors for the Company, improving stock liquidity and promoting the Company's reputation in the capital market. Looking forward, the Company will continuously devote to the exploration and development of RNAi therapeutics to bring benefits to patients and create value for its shareholders.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement  
July 1, 2025 16:00 HKT/SGT
JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers  
Tuesday, July 1, 2025 3:00:00 PM
GFEAI 2025 Concludes Successfully: PM Paetongtarn Backs Human-Centric AI, AIGPC Emerges as Regional AI Ethics Hub  
July 1, 2025 14:40 HKT/SGT
Fujitsu provides Japan's first AI-powered cloud-based library search service  
Tuesday, July 1, 2025 10:30:00 AM
JCB Brings Apple Pay to Cardmembers in Vietnam  
Tuesday, July 1, 2025 10:15:00 AM
First Shipment of LNG from the LNG Canada Project  
Tuesday, July 1, 2025 10:00:00 AM
Chinabank Fully Transitions Into AI-powered Human Capital Management  
July 1, 2025 08:00 HKT/SGT
HKIRA Announces Winners of the 11th IR Awards 2025  
July 1, 2025 00:20 HKT/SGT
Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier  
Monday, June 30, 2025 7:30:00 PM
Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier  
Monday, June 30, 2025 7:15:00 PM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: